TCT-54 The Influence of Smoking Status On The Pharmacodynamics of Prasugrel and Clopidogrel:The PARADOX Study

Paul A. Gurbel(Sinai Hospital), Brian Baker, Thomas D. Nolin(Yamaha (Japan)), Dominick J. Angiolillo(University of Florida), William L. Bailey(Daiichi Sankyo (United States)), Kenneth C. Lasseter, Kevin P. Bliden(Sinai Hospital), Udaya Tantry(Sinai Hospital), Clement K. Ojeh(Eli Lilly (United States)), Jen‐Fue Maa(Daiichi Sankyo (United States)), Alex E. White, Joseph A. Jakubowski(Indiana Biosciences Research Institute), Douglas Logan(Medpace (United States))

Journal of the American College of Cardiology

October 1, 2012

10.1016/j.jacc.2012.08.064

Cited by 3

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

|Circulation|2007|882

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

|New England Journal of Medicine|2013|825

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

|Circulation|2008|757

Ischemia and No Obstructive Coronary Artery Disease (INOCA)

|Circulation|2017|745

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

|New England Journal of Medicine|2013|651